SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
Phase 3
Completed
- Conditions
- RubellaJapanese EncephalitisMeaslesMumps
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 542
- Registration Number
- NCT01188343
Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
Phase 2
Completed
- Conditions
- Dengue Hemorrhagic FeverDengue
- Interventions
- Biological: NaCl 0.9%Biological: Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virusBiological: Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbedBiological: Meningococcal A+C vaccine
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 150
- Registration Number
- NCT01187433
A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants
Phase 3
Completed
- Conditions
- DiphtheriaTetanusWhooping CoughHepatitis BPoliomyelitis
- Interventions
- Biological: DTaP-IPV-Hep B-PRP-T VaccineBiological: DTaP-Hep B-IPV vaccine
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1375
- Registration Number
- NCT01177722
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza virus vaccine (split virion, inactivated)
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 129
- Registration Number
- NCT01138397
Post Marketing Surveillance for ADACEL™ in South Korea
Phase 4
Completed
- Conditions
- DiphtheriaTetanusPertussis
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 659
- Registration Number
- NCT01137435
Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia
Phase 3
Completed
- Conditions
- Dengue Hemorrhagic FeverDengue Fever
- Interventions
- Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 715
- Registration Number
- NCT01134263
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
Completed
- Conditions
- Pertussis
- Interventions
- Biological: Pentacel® (DTaP-IPV/Hib)Biological: Other Pertussis Vaccines
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1195
- Registration Number
- NCT01129362
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza virus vaccine (split virion, inactivated)
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 129
- Registration Number
- NCT01121822
A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
Phase 3
Completed
- Conditions
- EncephalitisJapanese Encephalitis
- Interventions
- Biological: Japanese encephalitis chimeric virus vaccine (JE-CV)Biological: Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2013-12-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 300
- Registration Number
- NCT01092507
A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults
Phase 2
Completed
- Conditions
- InfluenzaSwine-origin A/H1N1 Influenza
- Interventions
- Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated)
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 202
- Registration Number
- NCT01089660
© Copyright 2025. All Rights Reserved by MedPath